"Due to 27 different regulations in the EU alone (and more in other non-EU-countries), the administrative burden for international e-commerce is huge. Other than packaging regulations in many countries, WEEE regulations do typically not have any minimum thresholds or exceptions for SMEs. Therefore, WEEE registration and recycling fees are required in every country (separately – even within the EU) when shipping internationally. This also goes for startups and small stores which have just started selling electronics in Europe. (The laws even apply before the first sale is made.)"
The "No politics" at Coinbase refers to topics outside of the company's core mission. Regardless of what one thinks of lobbying, seeking beneficial regulation does not contradict the spirit of "no politics at work".
It's an online service. It has features to extract the whole story from the source website, and to automatically filter feed items according to title, author, tags etc. There are android and iOS apps available; at least the Android one is opensource.
One can self-host it, but at $36/year it's almost worth it paying the author to avoid the hassle.
Many of the issues on this article can be solved by turning the moderation problem on its head: instead of preventing users from posting any possibly offensive content, give users tools to choose which content they are exposed to (f.ex. prebuilt blocklists that can be customized with some granularity, and shared between users)
I don't know, if they are not going to implement the feature I almost prefer to be told right away. (Although a short explanation of some possible workarounds and/or a rationale for not implementing it would be tots).
I know it's just an example, but it seems to be more about sugarcoating than about being genuinely helpful.
(This is not Shingrix specific)
Before doing the large (Phase III) clinical trial that leads to approval, smaller trials in humans (Phase II) are done to test different doses and see how the body responds.
It is also a matter of risk management: assuming that two doses always create stronger immunity than one dose, it's better to do a successful Phase 3 trial with two doses and "miss out" on getting approval for a one-dose course, rather than aim for a one-shot vaccine, and risk the response being too small to get any approval at all.
Also, if the drug is successful in the market, Glaxo can do another trial to show that 1 dose is not inferior to 2 doses, and get a patent extension for the new formulation.
One mitigation is to start serving the feed at a new URL. This should fix things for new subscribers. The old subscribers can optionally be encouraged to change to the new URL manually via a specially crafted post in the old feed.
The Russian government intentions being what they are, still:
(i) This news can also be read as "Russia prepares for the possibility of being cut off from the global internet"
(ii) Having access to important services (government agencies, banks, etc.) without being reliant on private, foreign companies is not that bad of an idea, even for the most democratic of countries.